Bavarian Nordic continues trading high for 12th consecutive day, value spikes USD 1.4bn

The monkeypox outbreak hasn’t been all bad news -- at least not for the Danish vaccine maker.

Photo: Astrid Dalum

Everything Bavarian Nordic is turning gold -- particularly on the stock market, where trading of the company’s stock has advanced for the 12th day in a row.

All of last week, continuing to now, the Danish vaccine maker has been flying high, as orders for its monkeypox vaccine have rolled in, yielding several guidance upgrades. Things weren’t made worse either when the World Health Organization (WHO) declared monkeypox a global health crisis during the weekend.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs